Tau Pathology Cortical Neurons is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Tau pathology in cortical neurons is a hallmark of Alzheimer's disease and related tauopathies. Hyperphosphorylated tau accumulates into neurofibrillary tangles (NFTs), leading to synaptic loss, neuronal dysfunction, and ultimately cell death.
This page provides comprehensive information about the subject's role in neurodegenerative diseases. The subject participates in various molecular pathways and cellular processes relevant to Alzheimer's disease, Parkinson's disease, and related conditions.
- Microtubule stabilization
- Axonal transport support
- Neuronal polarity establishment
- Synaptic function modulation
- 6 isoforms in human brain (3R and 4R)
- Alternative splicing regulated by development
- Post-translational modifications
- Multiple phosphorylation sites
- GSK-3β: Major tau kinase
- CDK5: Neuronal tau kinase
- MAPK: Stress-activated kinases
- AMP: DYKs
- PP2A reduction in AD
- Reduced phosphatase activity
- Impaired dephosphorylation
- Caspase cleavage (Asp421)
- Calpain cleavage
- Generation of aggregation-prone fragments
- Hyperphosphorylated tau monomers
- Oligomeric intermediates
- Paired helical filaments
- Neurofibrillary tangles
- Loss of microtubule binding
- Increased self-aggregation
- Insoluble filament formation
- Cellular toxicity
- Layer II entorhinal cortex (earliest)
- Hippocampal CA1 neurons
- Layer III-V cortical pyramidal neurons
- Specific projection neurons
- High metabolic demand
- Extensive connectivity
- Tau expression patterns
- Axonal length
- Stage I-II: Transentorhinal (preclinical)
- Stage III-IV: Limbic (mild cognitive impairment)
- Stage V-VI: Isocortical (moderate-severe AD)
- NFT density correlates with cognitive decline
- Neuron loss exceeds tangle count
- Synaptic loss key correlate
- GSK-3β inhibitors
- CDK5 inhibitors
- LMTX (tau aggregation inhibitor)
- Anti-tau antibodies
- Active vaccination
- Antibody fragment approaches
- Tau aggregation inhibitors
- Microtubule stabilizers
- Protein turnover enhancers
- P301S tau transgenic neurons
- CRISPR-edited mutant tau
- iPSC-derived neurons
- Tau oligomer-treated cultures
- P301S transgenic mice
- 3xTg-AD mice
- Tau knockout studies
- AAV tau expression
- Total tau
- Phosphorylated tau
- Tau oligomers
- Tau PET ligands (1451AV-, MK-6240)
- Structural MRI atrophy patterns
- Functional connectivity changes
The study of Tau Pathology Cortical Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Braak & Braak, Neuropathological staging of Alzheimer-related changes (1991)
- Mandelkow & Mandelkow, Tau in physiology and pathology (2011)
- Iqbal et al., Tau pathology in Alzheimer disease and other tauopathies (2010)
- Goedert & Spillantini, Tau pathology and neurodegeneration (2011)